How RSV Vaccines Are Manufactured
RSV vaccines are manufactured using several distinct platform technologies, with the currently approved vaccines primarily utilizing recombinant protein subunit technology that expresses the stabilized prefusion F (preF) protein in cell culture systems, while newer generation vaccines employ mRNA-lipid nanoparticle (mRNA-LNP) platforms.
Current Approved Vaccine Manufacturing Approaches
Recombinant Protein Subunit Vaccines
The two currently available RSV vaccines (GSK's Arexvy/RSVPreF3 and Pfizer's Abrysvo/RSVpreF) are manufactured using recombinant protein technology 1. These vaccines:
- Target the fusion (F) protein - specifically the prefusion conformation (preF), which is the primary target because it elicits the most potent neutralizing antibodies 2
- Use mammalian cell culture systems - The RSV fusion glycoprotein is produced in Chinese hamster ovary (CHO) cells through recombinant DNA technology 3
- Employ protein stabilization techniques - The F protein is engineered to maintain its metastable prefusion state, as it naturally transitions from prefusion to postfusion during viral fusion 4, 2
- Undergo purification processes - The recombinant proteins are purified from cell culture, with optimization to remove host-cell proteins like hamster neogenin 3
mRNA-Lipid Nanoparticle (mRNA-LNP) Vaccines
Moderna's mResvia represents the newer mRNA platform 5:
- Encodes the preF protein - The mRNA sequence codes for the stabilized prefusion F protein
- Uses lipid nanoparticle delivery - The nucleoside-modified mRNA is encapsulated in lipid nanoparticles for cellular delivery and expression 4
- Enables in vivo protein production - Rather than manufacturing the protein directly, the vaccine delivers genetic instructions for cells to produce the antigen
Emerging Manufacturing Technologies
Advanced Nanoparticle Display Platforms
Research is advancing several innovative approaches 6, 7:
I53-50 nanoparticle platform - Genetically fuses RSV preF trimers to self-assembling protein scaffolds (I53-50A/B), creating spherical nanoparticles (50-60 nm) that display 20 preF antigens per particle, enhancing immunogenicity through multivalent antigen presentation 6
eVLP (enveloped virus-like particle) technology - Uses EABR (ESCRT- and ALIX-binding region) sequences to create self-assembling enveloped virus-like particles that display preF protein on their surface, inducing enhanced prefusion-specific antibody responses 7
Alternative Expression Systems
Historical and experimental approaches include:
- Plant-based production - RSV G-protein peptides expressed as translational fusions in tobacco plants through viral infection, though this represents older technology 8
Key Manufacturing Considerations
Antigen Selection and Engineering
The prefusion F protein is the preferred antigen because:
- The majority of highly neutralizing antibodies target the preF conformation 4, 2
- Natural infection predominantly induces postfusion-targeting antibodies, which are less protective
- Stabilizing the metastable preF structure requires specific molecular engineering 2
Quality Control Challenges
Manufacturing must address:
- Maintaining prefusion conformation throughout production and storage
- Removing host-cell contaminants like neogenin from CHO cell-produced vaccines 3
- Ensuring consistent antigen display for nanoparticle-based formulations 6
- Standardizing potency assays to measure functional antibody responses 2
Platform-Specific Advantages
Protein subunit vaccines offer:
- Established manufacturing infrastructure
- Well-characterized safety profiles
- Proven efficacy (75-82% effectiveness against hospitalization) 5
mRNA vaccines provide:
- Rapid development and manufacturing scalability
- Potential for enhanced cellular immunity (Th1-biased responses) 7, 4
- Flexibility for strain updates
Nanoparticle platforms demonstrate:
- Enhanced immunogenicity through multivalent display (2.3-2.8 fold higher neutralizing antibody titers) 6
- Improved B-cell affinity maturation and memory responses 6
Clinical Implications
The manufacturing method impacts vaccine performance - nanoparticle and mRNA platforms show promise for inducing more robust prefusion-specific immunity compared to conventional approaches, though only protein subunit vaccines currently have extensive real-world effectiveness data 5, 6, 7.